Head-to-head decision matrix

GLP-1 pharmacy index vs Pre-migration risk scan for businesses switching platforms

GLP-1 pharmacy index best fits the Research Strategist (36/100 fit), while Pre-migration risk scan for businesses switching platforms best fits the Operator Builder (78/100 fit). Choose by the founder advantage you can actually bring to the first validation sprint.

same vertical dataplus

Open GLP-1 pharmacy index Open Pre-migration risk scan for businesses switching platforms JSON

Retail & Local

GLP-1 pharmacy index

Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.

Verdict: Research / 51/100
Confidence: 55%
Difficulty: high
Founder fit: Researcher / 36/100
Proof average: 6.3/10

Read full report

Retail & Local

Pre-migration risk scan for businesses switching platforms

Replatforming projects routinely lose organic traffic, drop data, and break integrations because risks (un-redirected URLs, custom fields, app-stack dependencies, B2B workflows, SLA-sensitive integrations) are discovered mid-cutover instead of being surfaced and quantified up front while the old platform is still live.

Verdict: Research / 58/100
Confidence: 58%
Difficulty: moderate
Founder fit: Operator / 78/100
Proof average: 6.3/10

Read full report

Validation criteria

Same rubric, side by side.

Bars use the existing report visual scale, with each criterion scored out of 10.

Demand signal

GLP-1 pharmacy index 5.9/10

Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..

Pre-migration risk scan for businesses switching platforms 6/10

Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 58/100, and a defined buyer in Pre-migration readiness and risk-assessment tooling for businesses replatforming their e-commerce stack (e.g. Magento/WooCommerce to Shopify Plus or BigCommerce), sitting upstream of the $1B+ migration-services and migration-tooling ecosystem..

Problem severity

GLP-1 pharmacy index 6.3/10

Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.

Pre-migration risk scan for businesses switching platforms 6.3/10

Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.

Willingness to pay

GLP-1 pharmacy index 5/10

Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.

Pre-migration risk scan for businesses switching platforms 5.5/10

Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.

Competitive saturation

GLP-1 pharmacy index 3.9/10

Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.

Pre-migration risk scan for businesses switching platforms 4.7/10

Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.

Feasibility

GLP-1 pharmacy index 4/10

Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.

Pre-migration risk scan for businesses switching platforms 6.2/10

Feasibility is thin for a moderate build if the MVP is limited to the first measurable workflow.

Revenue and GTM

GLP-1 pharmacy index

Revenue: $250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.

GTM: Start with manual concierge output, direct outreach, and community proof before paid acquisition.

Execution: Execution is high; the main constraint is staying narrow enough for a first proof loop.

Pre-migration risk scan for businesses switching platforms

Revenue: $250K-$2M ARR potential if the wedge proves budget urgency and becomes a recurring workflow.

GTM: Start with manual concierge output, direct outreach, and community proof before paid acquisition.

Execution: Execution is moderate; the main constraint is staying narrow enough for a first proof loop.

Which founder should pick which?

GLP-1 pharmacy index: You spot uneven information quality, package evidence, and sell clarity to teams that make repeated decisions.
Pre-migration risk scan for businesses switching platforms: You win by improving a painful workflow you understand, then turning the repeatable part into software.